Podcast on the Management of Adverse Events Associated with Lorlatinib

por Bauer, Todd M., Bertino, Erin M.
Publicado 2022

From bench to bedside a comprehensive review of pancreatic cancer immunotherapy

por Kunk, Paul R., Bauer, Todd W., Slingluff, Craig L., Rahma, Osama E.
Publicado 2016

Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma

por Gamache, Awndre, Conarroe, Claire, Adair, Sara, Bauer, Todd, Padilla, Frederic, Bullock, Timothy N. J.
Publicado 2023

Automated biophysical classification of apoptotic pancreatic cancer cell subpopulations by using machine learning approaches with impedance cytometry

por Honrado, Carlos, Salahi, Armita, Adair, Sara J., Moore, John H., Bauer, Todd W., Swami, Nathan S.
Publicado 2022

Pancreatic duct size and gland texture are associated with pancreatic fistula after pancreaticoduodenectomy but not after distal pancreatectomy

por Martin, Allison N., Narayanan, Sowmya, Turrentine, Florence E., Bauer, Todd W., Adams, Reid B., Zaydfudim, Victor M.
Publicado 2018

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

por Bauer, Todd M, Patel, Manish R, Forero-Torres, Andres, George, Thomas J, Assad, Albert, Du, Yining, Hurwitz, Herbert
Publicado 2018

IgG4-Associated Cholangitis Can Mimic Hilar Cholangiocarcinoma

por Zaydfudim, Victor M., Wang, Andrew Y., de Lange, Eduard E., Zhao, Zimin, Moskaluk, Christopher A., Bauer, Todd W., Adams, Reid B.
Publicado 2015

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

por Moore, Kathleen N, Bauer, Todd M, Falchook, Gerald S, Chowdhury, Swapan, Patel, Chirag, Neuwirth, Rachel, Enke, Aaron, Zohren, Fabian, Patel, Manish R
Publicado 2018

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

por Brown, Jennifer, Plummer, Ruth, Bauer, Todd M., Anthony, Stephen, Sarantopoulos, John, De Vos, Filip, White, Mike, Schupp, Marco, Ou, Ying, Vaishampayan, Ulka
Publicado 2017

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

por Faessel, Hélène, Nemunaitis, John, Bauer, Todd M., Lockhart, A. Craig, Faller, Douglas V., Sedarati, Farhad, Zhou, Xiaofei, Venkatakrishnan, Karthik, Harvey, R. Donald
Publicado 2019

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer()

por Lindberg, James M., Newhook, Timothy E., Adair, Sara J., Walters, Dustin M., Kim, Alison J., Stelow, Edward B., Parsons, J. Thomas, Bauer, Todd W.
Publicado 2014

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

por Bauer, Todd M., Shaw, Alice T., Johnson, Melissa L., Navarro, Alejandro, Gainor, Justin F., Thurm, Holger, Pithavala, Yazdi K., Abbattista, Antonello, Peltz, Gerson, Felip, Enriqueta
Publicado 2020

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies

por Zhou, Xiaofei, Nemunaitis, John, Pant, Shubham, Bauer, Todd M., Patel, Manish, Sarantopoulos, John, Craig Lockhart, A., Goodman, Daniel, Huebner, Dirk, Mould, Diane R., Venkatakrishnan, Karthik
Publicado 2017

A Thirteen-Gene Expression Signature Predicts Survival of Patients with Pancreatic Cancer and Identifies New Genes of Interest

por Newhook, Timothy E., Blais, Edik M., Lindberg, James M., Adair, Sara J., Xin, Wenjun, Lee, Jae K., Papin, Jason A., Parsons, J. Thomas, Bauer, Todd W.
Publicado 2014

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

por Blank, Christian U., Wong, Deborah J., Ho, Thai H., Bauer, Todd M., Lee, Carrie B., Bene-Tchaleu, Fabiola, Zhu, Jing, Zhang, Xiaosong, Cha, Edward, Sznol, Mario
Publicado 2021

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

por Yap, Timothy A., Hamilton, Erika, Bauer, Todd, Dumbrava, Ecaterina E., Jeselsohn, Rinath, Enke, Aaron, Hurley, Sabrina, Lin, Kevin K., Habeck, Jenn, Giordano, Heidi, Shapiro, Geoffrey I.
Publicado 2022

The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

por LoRusso, Patricia, Yamamoto, Noboru, Patel, Manish R., Laurie, Scott A., Bauer, Todd M., Geng, Junxian, Davenport, Teffany, Teufel, Michael, Li, Jian, Lahmar, Mehdi, Gounder, Mrinal M.
Publicado 2023

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies

por Zhou, Xiaofei, Pant, Shubham, Nemunaitis, John, Craig Lockhart, A., Falchook, Gerald, Bauer, Todd M., Patel, Manish, Sarantopoulos, John, Bargfrede, Michael, Muehler, Andreas, Rangachari, Lakshmi, Zhang, Bin, Venkatakrishnan, Karthik
Publicado 2017

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

por Harding, James J., Bauer, Todd M., Tan, Daniel S. W., Bedard, Philippe L., Rodon, Jordi, Doi, Toshihiko, Schnell, Christian, Iyer, Varsha, Baffert, Fabienne, Radhakrishnan, Rajkumar, Fabre, Claire, Juric, Dejan
Publicado 2018

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study

por Piha-Paul, Sarina A., Taylor, Matthew H., Spitz, Daniel, Schwartzberg, Lee, Beck, J. Thaddeus, Bauer, Todd M., Meric-Bernstam, Funda, Purkayastha, Das, Karpiak, Linda, Szpakowski, Sebastian, Braiteh, Fadi
Publicado 2019